Search Results - "Bajorin, Dean"

Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis by Snyder, Alexandra, Nathanson, Tavi, Funt, Samuel A, Ahuja, Arun, Buros Novik, Jacqueline, Hellmann, Matthew D, Chang, Eliza, Aksoy, Bulent Arman, Al-Ahmadie, Hikmat, Yusko, Erik, Vignali, Marissa, Benzeno, Sharon, Boyd, Mariel, Moran, Meredith, Iyer, Gopa, Robins, Harlan S, Mardis, Elaine R, Merghoub, Taha, Hammerbacher, Jeff, Rosenberg, Jonathan E, Bajorin, Dean F

“…Inhibition of programmed death-ligand 1 (PD-L1) with atezolizumab can induce durable clinical benefit (DCB) in patients with metastatic urothelial cancers,…”
Get full text

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers by Teo, Min Yuen, Seier, Kenneth, Ostrovnaya, Irina, Regazzi, Ashley M, Kania, Brooke E, Moran, Meredith M, Cipolla, Catharine K, Bluth, Mark J, Chaim, Joshua, Al-Ahmadie, Hikmat, Snyder, Alexandra, Carlo, Maria I, Solit, David B, Berger, Michael F, Funt, Samuel, Wolchok, Jedd D, Iyer, Gopa, Bajorin, Dean F, Callahan, Margaret K, Rosenberg, Jonathan E

“…Purpose Alterations in DNA damage response and repair (DDR) genes are associated with increased mutation load and improved clinical outcomes in…”
Get full text

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study by Balar, Arjun V, Kamat, Ashish M, Kulkarni, Girish S, Uchio, Edward M, Boormans, Joost L, Roumiguié, Mathieu, Krieger, Laurence E M, Singer, Eric A, Bajorin, Dean F, Grivas, Petros, Seo, Ho Kyung, Nishiyama, Hiroyuki, Konety, Badrinath R, Li, Haojie, Nam, Kijoeng, Kapadia, Ekta, Frenkl, Tara, de Wit, Ronald

“…Standard treatment for high-risk non-muscle-invasive bladder cancer is transurethral resection of bladder tumour followed by intravesical BCG immunotherapy…”
Get full text

Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets by Pietzak, Eugene J, Bagrodia, Aditya, Cha, Eugene K, Drill, Esther N, Iyer, Gopa, Isharwal, Sumit, Ostrovnaya, Irina, Baez, Priscilla, Li, Qiang, Berger, Michael F, Zehir, Ahmet, Schultz, Nikolaus, Rosenberg, Jonathan E, Bajorin, Dean F, Dalbagni, Guido, Al-Ahmadie, Hikmat, Solit, David B, Bochner, Bernard H

“…Abstract Background Molecular characterization of nonmuscle invasive bladder cancer (NMIBC) may provide a biologic rationale for treatment response and novel…”
Get full text

Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy by GALSKY, Matthew D, HAHN, Noah M, BELLMUNT, Joaquim, ROSENBERG, Jonathan, SONPAVDE, Guru, HUTSON, Thomas, OH, William K, DREICER, Robert, VOGELZANG, Nicholas, STERNBERG, Cora N, BAJORIN, Dean F

“…Cisplatin-based combination chemotherapy is considered standard first-line treatment for patients with metastatic urothelial carcinoma. However, a large…”
Get full text

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma by Bellmunt, Joaquim, de Wit, Ronald, Vaughn, David J, Fradet, Yves, Lee, Jae-Lyun, Fong, Lawrence, Vogelzang, Nicholas J, Climent, Miguel A, Petrylak, Daniel P, Choueiri, Toni K, Necchi, Andrea, Gerritsen, Winald, Gurney, Howard, Quinn, David I, Culine, Stéphane, Sternberg, Cora N, Mai, Yabing, Poehlein, Christian H, Perini, Rodolfo F, Bajorin, Dean F

“…In a randomized trial involving 542 patients with relapsed urothelial cancer, treatment with pembrolizumab resulted in overall survival of more than 10 months,…”
Get full text

PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies by Reis, Henning, Serrette, Rene, Posada, Jennifer, Lu, Vincent, Chen, Ying-bei, Gopalan, Anuradha, Fine, Samson W, Tickoo, Satish K, Sirintrapun, Sahussapont J, Iyer, Gopa, Funt, Samuel A, Teo, Min Yuen, Rosenberg, Jonathan E, Bajorin, Dean F, Dalbagni, Guido, Bochner, Bernard H, Solit, David B, Reuter, Victor E, Al-Ahmadie, Hikmat A

“…The introduction of immune checkpoint blockade (ICB) therapy has transformed the management of advanced bladder cancer (BC). Despite its limitations, PD-L1…”
Get full text

Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma. Reply by Bajorin, Dean F, Collette, Sandra, Galsky, Matthew D

Get full text

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial by Rosenberg, Jonathan E, Dr, Hoffman-Censits, Jean, MD, Powles, Tom, Prof, van der Heijden, Michiel S, Prof, Balar, Arjun V, MD, Necchi, Andrea, MD, Dawson, Nancy, Prof, O'Donnell, Peter H, MD, Balmanoukian, Ani, MD, Loriot, Yohann, MD, Srinivas, Sandy, MD, Retz, Margitta M, Prof, Grivas, Petros, MD, Joseph, Richard W, MD, Galsky, Matthew D, MD, Fleming, Mark T, MD, Petrylak, Daniel P, Prof, Perez-Gracia, Jose Luis, MD, Burris, Howard A, MD, Castellano, Daniel, MD, Canil, Christina, MD, Bellmunt, Joaquim, MD, Bajorin, Dean, Prof, Nickles, Dorothee, PhD, Bourgon, Richard, PhD, Frampton, Garrett M, PhD, Cui, Na, PhD, Mariathasan, Sanjeev, PhD, Abidoye, Oyewale, MD, Fine, Gregg D, MD, Dreicer, Robert, Prof

“…Summary Background Patients with metastatic urothelial carcinoma have few treatment options after failure of platinum-based chemotherapy. In this trial, we…”
Get full text

Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy by Pietzak, Eugene J., Zabor, Emily C., Bagrodia, Aditya, Armenia, Joshua, Hu, Wenhuo, Zehir, Ahmet, Funt, Samuel, Audenet, Francois, Barron, David, Maamouri, Noelia, Li, Qiang, Teo, Min Yuen, Arcila, Maria E., Berger, Michael F., Schultz, Nikolaus, Dalbagni, Guido, Herr, Harry W., Bajorin, Dean F., Rosenberg, Jonathan E., Al-Ahmadie, Hikmat, Bochner, Bernard H., Solit, David B., Iyer, Gopa

“…Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is the standard of care for patients with muscle-invasive bladder cancer…”
Get full text

Genome Sequencing Identifies a Basis for Everolimus Sensitivity by Iyer, Gopa, Hanrahan, Aphrothiti J., Milowsky, Matthew I., Al-Ahmadie, Hikmat, Scott, Sasinya N., Janakiraman, Manickam, Pirun, Mono, Sander, Chris, Socci, Nicholas D., Ostrovnaya, Irina, Viale, Agnes, Heguy, Adriana, Peng, Luke, Chan, Timothy A., Bochner, Bernard, Bajorin, Dean F., Berger, Michael F., Taylor, Barry S., Solit, David B.

“…Cancer drugs often induce dramatic responses in a small minority of patients. We used whole-genome sequencing to investigate the genetic basis of a durable…”
Get full text

Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma by Holm, Jeppe Sejerø, Funt, Samuel A., Borch, Annie, Munk, Kamilla Kjærgaard, Bjerregaard, Anne-Mette, Reading, James L., Maher, Colleen, Regazzi, Ashley, Wong, Phillip, Al-Ahmadie, Hikmat, Iyer, Gopa, Tamhane, Tripti, Bentzen, Amalie Kai, Herschend, Nana Overgaard, De Wolf, Susan, Snyder, Alexandra, Merghoub, Taha, Wolchok, Jedd D., Nielsen, Morten, Rosenberg, Jonathan E., Bajorin, Dean F., Hadrup, Sine Reker

“…CD8 + T cell reactivity towards tumor mutation-derived neoantigens is widely believed to facilitate the antitumor immunity induced by immune checkpoint…”
Get full text

DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma by Teo, Min Yuen, Bambury, Richard M, Zabor, Emily C, Jordan, Emmet, Al-Ahmadie, Hikmat, Boyd, Mariel E, Bouvier, Nancy, Mullane, Stephanie A, Cha, Eugene K, Roper, Nitin, Ostrovnaya, Irina, Hyman, David M, Bochner, Bernard H, Arcila, Maria E, Solit, David B, Berger, Michael F, Bajorin, Dean F, Bellmunt, Joaquim, Iyer, Gopakumar, Rosenberg, Jonathan E

“…Platinum-based chemotherapy remains the standard treatment for advanced urothelial carcinoma by inducing DNA damage. We hypothesize that somatic alterations in…”
Get full text

Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer by Vaughn, David J, Bellmunt, Joaquim, Fradet, Yves, Lee, Jae Lyun, Fong, Lawrence, Vogelzang, Nicholas J, Climent, Miguel A, Petrylak, Daniel P, Choueiri, Toni K, Necchi, Andrea, Gerritsen, Winald, Gurney, Howard, Quinn, David I, Culine, Stephane, Sternberg, Cora N, Mai, Yabing, Li, Haojie, Perini, Rodolfo F, Bajorin, Dean F, de Wit, Ronald

“…Purpose In the phase III KEYNOTE-045 study ( ClinicalTrials.gov identifier: NCT02256436), pembrolizumab significantly prolonged overall survival compared with…”
Get full text

Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer by IYER, Gopa, AL-AHMADIE, Hikmat, ZABOR, Emily C, JANAKIRAMAN, Manickam, GARCIA-GROSSMAN, Ilana R, HEGUY, Adriana, VIALE, Agnes, BOCHNER, Bernard H, REUTER, Victor E, BAJORIN, Dean F, MILOWSKY, Matthew I, TAYLOR, Barry S, SCHULTZ, Nikolaus, SOLIT, David B, HANRAHAN, Aphrothiti J, OSTROVNAYA, Irina, BALAR, Arjun V, KIM, Philip H, LIN, Oscar, WEINHOLD, Nils, SANDER, Chris

“…We sought to define the prevalence and co-occurrence of actionable genomic alterations in patients with high-grade bladder cancer to serve as a platform for…”
Get full text

Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU) by Rosenberg, Jonathan E, Park, Se Hoon, Kozlov, Vadim, Dao, Tu V, Castellano, Daniel, Li, Jian-Ri, Mukherjee, Som D, Howells, Kathryn, Dry, Hannah, Lanasa, Mark C, Stewart, Ross, Bajorin, Dean F

“…Homologous recombination repair gene mutations (HRRm) are common in urothelial carcinoma (UC), rendering tumor cells sensitive to poly (ADP-ribose) polymerase…”
Get full text

Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors by Sonpavde, Guru, Manitz, Juliane, Gao, Chen, Tayama, Darren, Kaiser, Constanze, Hennessy, Daniel, Makari, Doris, Gupta, Ashok, Abdullah, Shaad Essa, Niegisch, Guenter, Rosenberg, Jonathan E, Bajorin, Dean F, Grivas, Petros, Apolo, Andrea B, Dreicer, Robert, Hahn, Noah M, Galsky, Matthew D, Necchi, Andrea, Srinivas, Sandy, Powles, Thomas, Choueiri, Toni K, Pond, Gregory R

“…A prognostic model for overall survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-1/PD-L1 inhibitors is necessary as existing…”
Get full text

A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy by Galsky, Matthew D, Hahn, Noah M, Rosenberg, Jonathan, Sonpavde, Guru, Hutson, Thomas, Oh, William K, Dreicer, Robert, Vogelzang, Nicholas, Sternberg, Cora, Bajorin, Dean F, Bellmunt, Joaquim

Get full text

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations by Pal, Sumanta K, Rosenberg, Jonathan E, Hoffman-Censits, Jean H, Berger, Raanan, Quinn, David I, Galsky, Matthew D, Wolf, Juergen, Dittrich, Christian, Keam, Bhumsuk, Delord, Jean-Pierre, Schellens, Jan H M, Gravis, Gwenaelle, Medioni, Jacques, Maroto, Pablo, Sriuranpong, Virote, Charoentum, Chaiyut, Burris, Howard A, Grünwald, Viktor, Petrylak, Daniel, Vaishampayan, Ulka, Gez, Eliahu, De Giorgi, Ugo, Lee, Jae-Lyun, Voortman, Jens, Gupta, Sumati, Sharma, Sunil, Mortazavi, Amir, Vaughn, David J, Isaacs, Randi, Parker, Katie, Chen, Xueying, Yu, Kun, Porter, Dale, Graus Porta, Diana, Bajorin, Dean F

“…BGJ398, a potent and selective pan-FGFR antagonist, was prospectively evaluated in patients with metastatic urothelial carcinoma bearing a diverse array of…”
Get more information

Association Between Geographic Access to Cancer Care, Insurance, and Receipt of Chemotherapy: Geographic Distribution of Oncologists and Travel Distance by Lin, Chun Chieh, Bruinooge, Suanna S, Kirkwood, M Kelsey, Olsen, Christine, Jemal, Ahmedin, Bajorin, Dean, Giordano, Sharon H, Goldstein, Michael, Guadagnolo, B Ashleigh, Kosty, Michael, Hopkins, Shane, Yu, James B, Arnone, Anna, Hanley, Amy, Stevens, Stephanie, Hershman, Dawn L

“…Geographic access to care may be associated with receipt of chemotherapy but has not been fully examined. This study sought to evaluate the association between…”
Get full text